ArticlePloS one2013
Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Liposomes from red betel (Open veterinary journal · 2025Pooled it
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- Lipid-based nanocarriers for enhanced gentamicin delivery: a comparative study of liquid crystal nanoparticles and liposomes against Escherichia coli biofilms.Drug delivery and translational research · 2025Article
- Cholesterol-Rich Antibiotic-Loaded Liposomes as Efficient Antimicrobial Therapeutics.International journal of nanomedicine · 2025Article
- Effectiveness of a Novel Liposomal Methylglyoxal-Tobramycin Formulation in Reducing Biofilm Formation and Bacterial Adhesion.Antibiotics (Basel, Switzerland) · 2024Article
- Colloidal Structure Dictates Antimicrobial Efficacy in LL-37 Self-Assemblies With Glycerol Monooleate.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Daptomycin Liposomes Exhibit Enhanced Activity against Staphylococci Biofilms Compared to Free Drug.Pharmaceutics · 2024Article
- New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.Antibiotics (Basel, Switzerland) · 2024Review
- Enzyme-Linked Lipid Nanocarriers for Coping Pseudomonal Pulmonary Infection. Would Nanocarriers Complement Biofilm Disruption or Pave Its Road?International journal of nanomedicine · 2024Article
- Article
- Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives.Drug delivery · 2022Review
- Tobramycin Nanoantibiotics and Their Advantages: A Minireview.International journal of molecular sciences · 2022Review
- Biofilm antimicrobial susceptibility through an experimental evolutionary lens.NPJ biofilms and microbiomes · 2022Review
- Tobramycin-loaded complexes to prevent and disrupt Pseudomonas aeruginosa biofilms.Drug delivery and translational research · 2022Article
- Neutralization of ionic interactions by dextran-based single-chain nanoparticles improves tobramycin diffusion into a mature biofilm.NPJ biofilms and microbiomes · 2022Article
- Recent Advances in Antimicrobial Nano-Drug Delivery Systems.Nanomaterials (Basel, Switzerland) · 2022Review
- Moxifloxacin Liposomes: Effect of Liposome Preparation Method on Physicochemical Properties and Antimicrobial Activity againstPharmaceutics · 2022Article
- Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin andPharmaceutics · 2022Article
- Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy.Drug delivery and translational research · 2021Review
- Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections.Drug delivery and translational research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the intrinsic resistance of Burkholderia cepacia complex (Bcc) to many antibiotics and the production of a broad range of virulence factors, lung infections by these bacteria, primarily occurring in cystic fibrosis (CF) patients, are very difficult to treat. In addition, the ability of Bcc organisms to form biofilms contributes to their persistence in the CF lung. As Bcc infections are associated with poor clinical outcome, there is an urgent need for new effective therapies to treat these infections. In the present study, we investigated whether liposomal tobramycin displayed an increased anti-biofilm effect against Bcc bacteria compared to free tobramycin. Single particle tracking (SPT) was used to study the transport of positively and negatively charged nanospheres in Bcc biofilms as a model for the transport of liposomes. Negatively charged nanospheres became immobilized in close proximity of biofilm cell clusters, while positively charged nanospheres interacted with fiber-like structures, probably eDNA. Based on these data, encapsulation of tobramycin in negatively charged liposomes appeared promising for targeted drug delivery. However, the anti-biofilm effect of tobramycin encapsulated into neutral or anionic liposomes did not increase compared to that of free tobramycin. Probably, the fusion of the anionic liposomes with the negatively charged bacterial surface of Bcc bacteria was limited by electrostatic repulsive forces. The lack of a substantial anti-biofilm effect of tobramycin encapsulated in neutral liposomes could be further investigated by increasing the liposomal tobramycin concentration. However, this was hampered by the low encapsulation efficiency of tobramycin in these liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.